INTERLEUKIN 3 RECEPTOR (CD123) EXPRESSION IN ACUTE MYELOID LEUKAEMIA PATIENTS IN RELATION TO DISEASE CHARACTERISTICS AND TREATMENT OUTCOME
Ghandor, A., Donia, H., Nadwan, E., Mohamed Kamel, M. (2023). INTERLEUKIN 3 RECEPTOR (CD123) EXPRESSION IN ACUTE MYELOID LEUKAEMIA PATIENTS IN RELATION TO DISEASE CHARACTERISTICS AND TREATMENT OUTCOME. EKB Journal Management System, 5(1), 47-48. doi: 10.21608/alexpo.2023.200513.1591
Ashraf Ghandor; Hana Ali Donia; Eman Nadwan; Mona Ehab Mohamed Kamel. "INTERLEUKIN 3 RECEPTOR (CD123) EXPRESSION IN ACUTE MYELOID LEUKAEMIA PATIENTS IN RELATION TO DISEASE CHARACTERISTICS AND TREATMENT OUTCOME". EKB Journal Management System, 5, 1, 2023, 47-48. doi: 10.21608/alexpo.2023.200513.1591
Ghandor, A., Donia, H., Nadwan, E., Mohamed Kamel, M. (2023). 'INTERLEUKIN 3 RECEPTOR (CD123) EXPRESSION IN ACUTE MYELOID LEUKAEMIA PATIENTS IN RELATION TO DISEASE CHARACTERISTICS AND TREATMENT OUTCOME', EKB Journal Management System, 5(1), pp. 47-48. doi: 10.21608/alexpo.2023.200513.1591
Ghandor, A., Donia, H., Nadwan, E., Mohamed Kamel, M. INTERLEUKIN 3 RECEPTOR (CD123) EXPRESSION IN ACUTE MYELOID LEUKAEMIA PATIENTS IN RELATION TO DISEASE CHARACTERISTICS AND TREATMENT OUTCOME. EKB Journal Management System, 2023; 5(1): 47-48. doi: 10.21608/alexpo.2023.200513.1591

INTERLEUKIN 3 RECEPTOR (CD123) EXPRESSION IN ACUTE MYELOID LEUKAEMIA PATIENTS IN RELATION TO DISEASE CHARACTERISTICS AND TREATMENT OUTCOME

ALEXMED ePosters
Article 1, Volume 5, Issue 1, January 2023, Page 47-48  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2023.200513.1591
View on SCiNiTO View on SCiNiTO
Authors
Ashraf Ghandor1; Hana Ali Donia2; Eman Nadwan3; Mona Ehab Mohamed Kamel email 4
1Professor of Internal Medicine, Haematology unit ,Faculty of Medicine,University of Alexandria.
2Clinical Pathology Department, Faculty of Medicine; Alexandria University, Egypt.
3Department of Internal Medicine (Hematology Unit), Faculty of Medicine , Alexandria University
4Department of internal medicine, Haematology Unit,Faculty of Medicine, University of Alexandria.
Abstract
INTRODUCTION:
In spite of the remarkable progress in basic and preclinical studies of acute myeloid leukemia (AML), the five-year survival rate of AML patients remains poor, highlighting the urgent need for novel and synergistic therapies.
Over the past decade, increased attention has been focused on identifying suitable immunotherapeutic strategies for AML, and in particular on targeting leukemic cells and their progenitors. However, the clinical outcome of patients with acute myeloid leukemia (AML) remains suboptimal, despite recent approval of new promising targeted therapies.
With the evolution of targeted AML therapies, novel agents continue to be developed with the goal to improve efficacy while minimizing toxicity.
CD123 (alpha subunit of the interleukin 3 receptor) is a cell membrane protein overexpressed in several hematologic malignancies which makes it an attractive therapeutic target.
It is composed of three extracellular domains (287 amino acids), a single-pass trans membrane domain (30 amino acids), and a short intracellular region (53 amino acids).
Upon lig and binding, the IL-3R heterodimer comprised of alpha and beta chains signals through Jak2, leading to a downstream activation of effectors that result in a net increase of cell proliferation and survival.
Keywords
DISEASE; INTERLEUKIN; LEUKAEMIA
Supplementary Files
Statistics
Article View: 95